Terray is ending the year on a high. Just two short months ago the biotech came out with a healthy $120 million series B ...

(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with ...

Gilead Sciences, Inc. (GILD) and Terray Therapeutics, Inc. announced Tuesday that the companies have entered into a strategic ...

Gilead Sciences Inc. closed $6.85 short of its 52-week high ($98.90), which the company achieved on November 11th.

Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal.

US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop ...

Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.

Gilead Sciences (GILD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- ...

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...

For years, Gilead Sciences was dead money for shareholders. Shares of the drugmaker, with a market capitalization of just ...

At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a ...

Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...